Market News & Trends
Vetter Des Plaines Facility is the German American Chamber of Commerce’s Investment of the Year
The German American Chamber of Commerce awarded Vetter, a globally operating pharmaceutical service provider, the Investment of the Year Award 2026. The award was officially…
Neuland to Open Commercial Peptide Facility as part of Planned Phased Expansion
Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned…
Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
-Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO (betibeglogene autotemcel), the only FDA-approved gene therapy for…
Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
Centauri Therapeutics Limited recently announced the its lead clinical candidate in the ABX-01 program, CTX-187, has received Qualified Infectious Disease Product (QIDP) designation from the…
Upperton Submits MHRA License Application for Annex 1 Sterile Manufacturing Facility Following APS Validation
Upperton has submitted its application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the approval of its new 7,000 sq. ft sterile…
Biologos Appoints New CEO, Celebrates 50 Years of Growth & Innovation
Biologos recently announced the appointment of Hetal Patel as Chief Executive Officer.
Medicus Pharma Reports Positive Phase 2 Topline Data Observing 73% Clinical Clearance & 40% Histological Clearance
Medicus Pharma Ltd. recently announced topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively…
LabVantage Solutions Introduces LabVantage CORTEX, Advancing its LIMS Platform for AI-Driven Laboratory Operations
LabVantage Solutions, Inc. recently announced the launch of LabVantage CORTEX, a next-generation artificial intelligence (AI), analytics, and automation platform. The launch represents a strategic evolution…
Codexis Signs Agreement to Manufacture 50 g siRNA Using its ECO Synthesis Manufacturing Platform
Codexis, Inc. recently announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using…
FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology
FUJIFILM Biotechnologies recently unveiled ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will be presented this week at the Festival…
BioDuro & Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity
BioDuro recently announced it has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB),…
NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
NorthSea Therapeutics B.V. recently announced the US FDA and the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) have granted Orphan Drug Designations…
ESTEVE CDMO Commences $15.5 Million Expansion of Chicago Small Molecule API Facility
ESTEVE CDMO recently announced it had commenced a $15.5-million investment to enhance production capabilities and associated space at its newly acquired North American facility in…
Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19
Bioxytran, Inc. recently announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused…
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Quotient Sciences recently announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an…
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Neurizon Therapeutics Limited recently announced the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon’s lead candidate, NUZ-001,…
MGS Acquires European-Based Medical Injection Molder Knudsen Plast A/S
MGS recently announced the acquisition of Knudsen Plast A/S, a premier Denmark-based injection molder with more than 40 years of dedicated healthcare manufacturing experience. With…
TARA-002 Demonstrates 68% Complete Response Rate at 6 Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Protara Therapeutics, Inc. recently announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in…
etherna´s Intratumoral mRNA/LNP Platform Advances to Clinical Testing in Nonmelanoma Skin Cancer Led by Almirall
etherna recently announced one of its key collaborators, Almirall, a leading medical dermatology company, nominated LAD116 as a novel therapy targeting non-melanoma skin cancer for…
SolasCure Completes Phase 2 Clinical Trial Demonstrating Accelerated Healing With Aurase Wound Gel
SOLASCURE Ltd recently announced the successful completion of its second Phase 2 clinical trial, CLEANVLU2. The study demonstrated that its investigational product, Aurase Wound Gel…
